JulianMackay-WigganMD(She/Her)

Professor, New York University-Langone Health Former Dermatologist, Siperstein Dermatology Former Associate Professor, Dermatology, Columbia University College of Physicians & Surgeons Medical consultant

Join to view full profile

Dr. Mackay-Wiggan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mackay-Wiggan's full profile

Already have an account?

Office
101 N Clematis St
Suite 110
West Palm Beach, FL 33401
Phone+1 561-365-3000

Summary

Dermatology and Research Consultant

Education & Training

Columbia University School of Public HealthMS, Patient Oriented Research, 2002 - 2004
New York Presbyterian Hospital (Columbia Campus)Residency, Dermatology, 1999 - 2002
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1998 - 1999
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998

Certifications & Licensure

NY State Medical License 2002 - 2026
FL State Medical License 2017 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails Start of enrollment: 2005 Aug 01
Completed
Phase 4
Open Label Pilot Study of Apremilast in Treatment of Rosacea Start of enrollment: 2010 Jun 01
Completed
Phase 2
Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis Start of enrollment: 2011 Sep 01
Withdrawn
Phase 2
Intralesional Steroids in the Treatment of Alopecia Areata Start of enrollment: 2011 Sep 01
Terminated
Phase 4
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata Start of enrollment: 2013 Aug 01
Withdrawn
Phase 2
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Start of enrollment: 2013 Aug 01
Completed
Phase 2
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Start of enrollment: 2013 Sep 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

604 citations
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing, Z. Dai, Ali Jabbari, Jane E. Cerise, Claire A. Higgins
Nature Medicine. 2014-09-01
136 citations
Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).
Julian Mackay-Wiggan, David J. Cohen, Mark A. Hardy, Elizabeth Knobler, Marc E. Grossman
Journal of the American Academy of Dermatology. 2003-01-01
73 citations
Prospective study of wound infections in Mohs micrographic surgery using clean surgical technique in the absence of prophylactic antibiotics
Heather D. Rogers, Edward B. Desciak, Rebecca Marcus, Shuang Wang, Julian Mackay-Wiggan
Journal of the American Academy of Dermatology. 2010-11-01

Press Mentions

Cure for Hair Loss Has Finally Been FoundSeptember 26th, 2016
FDA-Approved Drug Restores Hair in Patients with Alopecia AreataAugust 18th, 2014
Alopecia Patients in Study Grow Hair with New DrugAugust 17th, 2014